In conclusion, our study revealed the following: (1) Elevated TLR2 levels were observed in PV and ET patients compared to MF (Figure 1(a)); (2) TLR2 levels were associated with Jak2 mutations (Figure 4(a)) and leukocytosis (Figure 4(b)); (3) enhanced in vitro LPI was induced by PM3CSK4 (a TLR2 agonist), but not by LPS (a TLR4 agonist), and this response was markedly diminished by a TLR2 inhibitor, but not by a TLR4 inhibitor (Figures 6(a) and 6(b), clinical evidence showed that patients with elevated TLR2 levels experience more thrombosis than patients with normal TLR2 levels. This evidence concerns the gene TLR4 and Venous thrombosis.